The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Human Antibodies against a Purified Glucosylceramide from Cryptococcus neoformans Inhibit Cell Budding and Fungal Growth
Open accessAbstract
A major ceramide monohexoside (CMH) was purified from lipidic extracts of Cryptococcus neoformans. This molecule was analyzed by high-performance thin-layer chromatography (HPTLC), gas chromatography coupled with mass spectrometry, and fast atom bombardment-mass spectrometry. The cryptococcal CMH is a β-glucosylceramide, with the carbohydrate residue attached to 9-methyl-4,8-sphingadienine in amidic linkage to 2-hydroxyoctadecanoic acid. Sera from patients with cryptococcosis and a few other mycoses reacted with the cryptococcal CMH. Specific antibodies were purified from patients' sera by immunoadsorption on the purified glycolipid followed by protein G affinity chromatography. The purified antibodies to CMH (mainly immunoglobulin G1) bound to different strains and serological types of C. neoformans, as shown by flow cytofluorimetry and immunofluorescence labeling. Transmission electron microscopy of yeasts labeled with immunogold-antibodies to CMH and immunostaining of isolated cell wall lipid extracts separated by HPTLC showed that the cryptococcal CMH predominantly localizes to the fungal cell wall. Confocal microscopy revealed that the β-glucosylceramide accumulates mostly at the budding sites of dividing cells with a more disperse distribution at the cell surface of nondividing cells. The increased density of sphingolipid molecules seems to correlate with thickening of the cell wall, hence with its biosynthesis. The addition of human antibodies to CMH to cryptococcal cultures of both acapsular and encapsulated strains of C. neoformans inhibited cell budding and cell growth. This process was complement-independent and reversible upon removal of the antibodies. The present data suggest that the cryptococcal β-glucosylceramide is a fungal antigen that plays a role on the cell wall synthesis and yeast budding and that antibodies raised against this component are inhibitory in vitro.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cryptococcus neoformans Is a Facultative Intracellular Pathogen in Murine Pulmonary Infection
Feldmesser, M., Kress, Y., Novikoff, P., & Casadevall, A. (2000) · Infection and Immunity · doi:10.1128/iai.68.7.4225-4237.2000 · Cited by 423
The antibody response to fungal melanin in mice
Nosanchuk, J. D., Rosas, A. L., & Casadevall, A. (1998) · The Journal of Immunology · doi:10.4049/jimmunol.160.12.6026 · Cited by 92
Cited by
Beyond binding: antibody effector functions in infectious diseases
Lu, L. L., Suscovich, T. J., Fortune, S. M., & Alter, G. (2018) · Nature Reviews Immunology · doi:10.1038/nri.2017.106 · Cited by 825
Passive antibody therapy for infectious diseases
Casadevall, A., Dadachova, E., & Pirofski, L.-A. (2004) · Nature Reviews Microbiology · doi:10.1038/nrmicro974 · Cited by 531
Chapter 4 The Capsule of the Fungal Pathogen Cryptococcus neoformans
Zaragoza, O., Rodrigues, M. L., De Jesus, M., Frases, S., Dadachova, E., & Casadevall, A. (2009) · Advances in Applied Microbiology · doi:10.1016/s0065-2164(09)01204-0 · Cited by 457
Self-citationAn insight into the antifungal pipeline: selected new molecules and beyond
Ostrosky-Zeichner, L., Casadevall, A., Galgiani, J. N., Odds, F. C., & Rex, J. H. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3074 · Cited by 432
Perfect, J. R., & Casadevall, A. (2002) · Infectious Disease Clinics of North America · doi:10.1016/s0891-5520(02)00036-3 · Cited by 363
Metadata
- Authors
- Rodrigues, M. L., Travassos, L. R., Miranda, K. R., Franzen, A. J., Rozental, S., de Souza, W., Alviano, C. S., & Barreto-Bergter, E.
- Venue
- Infection and Immunity
- Publisher
- American Society for Microbiology
- Published
- 2000-12
- Volume
- 68
- Issue
- 12
- Pages
- 7049-7060
- ISSN
- 0019-9567 (ISSN-L)
- 1098-5522
- OpenAlex
- W1964576347
- Cited by
- 218
- References
- 2
- FWCI
- 4.12
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Human Antibodies against a Purified Glucosylceramide from Cryptococcus neoformans Inhibit Cell Budding and Fungal Growth. https://app.cochat.ai/papers/10.1128/iai.68.12.7049-7060.2000
- The paper
- Rodrigues, M. L., Travassos, L. R., Miranda, K. R., Franzen, A. J., Rozental, S., de Souza, W., Alviano, C. S., & Barreto-Bergter, E. (2000). Human Antibodies against a Purified Glucosylceramide from Cryptococcus neoformans Inhibit Cell Budding and Fungal Growth. Infection and Immunity. https://doi.org/10.1128/iai.68.12.7049-7060.2000
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.